These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 1966985)
1. The development of cell mediated immunity: very young children have strong LAK activity. Pierson GR; Evans AE; Zier KS J Clin Lab Immunol; 1990 Feb; 31(2):51-4. PubMed ID: 1966985 [TBL] [Abstract][Full Text] [Related]
2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
3. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma. Muralikrishna K; Varalakshmi C; Khar A Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244 [TBL] [Abstract][Full Text] [Related]
4. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells. de Fries RU; Golub SH J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500 [TBL] [Abstract][Full Text] [Related]
5. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355 [TBL] [Abstract][Full Text] [Related]
6. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
7. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628 [TBL] [Abstract][Full Text] [Related]
8. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes. Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597 [TBL] [Abstract][Full Text] [Related]
9. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186 [TBL] [Abstract][Full Text] [Related]
10. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272 [TBL] [Abstract][Full Text] [Related]
11. Thrombin modulation of natural killer activity in human peripheral lymphocytes. Naldini A; Carney DH Cell Immunol; 1996 Aug; 172(1):35-42. PubMed ID: 8806804 [TBL] [Abstract][Full Text] [Related]
12. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma. Blanchard DK; Djeu JY J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557 [TBL] [Abstract][Full Text] [Related]
13. Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity. Wu R; Coleman N; Stanley M Chin Med J (Engl); 1996 Nov; 109(11):854-8. PubMed ID: 9275369 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid. Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887 [TBL] [Abstract][Full Text] [Related]
15. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512 [TBL] [Abstract][Full Text] [Related]
16. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers. Nio Y; Zighelboim J; Berek JS; Bonavida B Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516 [TBL] [Abstract][Full Text] [Related]
17. Natural killer (NK) cell subsets in the mouse. NK-1.1+/LGL-1+ cells restricted to lysing NK targets, whereas NK-1.1+/LGL-1- cells generate lymphokine-activated killer cells. Mason LH; Mathieson BJ; Ortaldo JR J Immunol; 1990 Jul; 145(2):751-9. PubMed ID: 2365999 [TBL] [Abstract][Full Text] [Related]
18. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. Gunji Y; Lewis J; Gorelik E Blood Coagul Fibrinolysis; 1990 Dec; 1(6):663-72. PubMed ID: 2133246 [TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor. Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733 [TBL] [Abstract][Full Text] [Related]
20. Lysis of human solid tumor cells by lymphokine-activated natural killer cells. Itoh K; Tilden AB; Balch CM J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]